Transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery

Recommendation for NHSScotland

• Despite remaining uncertainty over cost effectiveness and the safety issues associated with the use of TAVI in patients ineligible for surgery, the evidence of clinical benefit supports the use of TAVI for inoperable patients and the ongoing collection of patient selection and outcome data.
• TAVI technology continues to evolve. Rapid progress is being made in device modification and patient selection such that the published evidence base may not fully capture the emergent evidence for the latest generation of TAVI devices.
• The National Planning Forum TAVI expert review and clinical oversight groups will continue to monitor the operation and outcomes of the national TAVI service.

NHSScotland is required to consider the Scottish Health Technologies Group (SHTG) advice.

What were we asked to look at?

Clinical and cost effectiveness of transcatheter aortic valve implantation (TAVI) for severe symptomatic aortic stenosis in adults who are not eligible for surgery.

Referred by

National Planning Forum TAVI Review Group